Search form
Search
contact us
Navigation
home
boards
job center
job ratings
cp wire
device news
pharmagather
catering
advertise
Legal Help
login/register
You are here
Home
»
companies
» ENMD-2076
ENMD-2076
EntreMed commences ENMD-2076 Phase 2 trial
EntreMed commences ENMD-2076 Phase 2 trial
The Fly on the Wall
ENMD-2076
EntreMed
ovarian cancer
Flag link:
EntreMed announces initiation of phase 2 trial in triple-negative breast cancer
EntreMed announces initiation of phase 2 trial in triple-negative breast cancer
Yahoo/Fly on the Wall
EntreMed
triple-negative breast cancer
breast cancer
ENMD-2076
Flag link:
EntreMed shares spike on PhII cancer data
EntreMed shares spike on PhII cancer data
Fierce Biotech
EntreMed
ENMD-2076
ovarian cancer
Flag link:
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
Yahoo/PR NewsWire
EntreMed
ENMD-2076
ovarian cancer
Flag link:
Six Trades on FDA, Clinical Trial Binary Events
Six Trades on FDA, Clinical Trial Binary Events
Seeking Alpha
BioSante
LibiGel
testosterone
EntreMed
ENMD-2076
cancer
Protalix BioTherapeutics
UPLYSO
ovarian cancer
Vivus
Qnexa
obesity
EMD 640744
cancer vaccines
Flag link:
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
Yahoo/PR NewsWire
EntreMed
ENMD-2076
Aurora A/angiogenic kinase inhibitor
ovarian cancer
Flag link: